Nisha Marathe
Direttore/Membro del Consiglio presso Soteria Biotherapeutics, Inc.
Profilo
Nisha Marathe has worked as an Investment Director at Roche Ventures since 2020.
She is also currently a Director at Soteria Biotherapeutics, Inc.
Posizioni attive di Nisha Marathe
| Società | Posizione | Inizio |
|---|---|---|
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Investitore di Private Equity | 01/01/2018 |
Soteria Biotherapeutics, Inc.
 Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
Soteria Biotherapeutics, Inc.
Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Nisha Marathe
